Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts

• DOI: 10.21147/j.issn.1000-9604.2021.04.04
• Publication Date: 2021-09-09T02:29:17Z
• Authors: Jianyong Zhuo; ; Di Lu; Jianguo Wang; Zhengxing Lian; Jiali Zhang; Huihui Li; Beini Cen; Xuyong Wei; Qiang Wei; Haiyang Xie; Xiao Xu
• Keywords: Glypican 3

Patient-derived xenograft (PDX) models provide a promising preclinical platform for hepatocellular carcinoma (HCC). However, the molecular features associated with successful engraftment of PDX have not been revealed.HCC tumor samples from 76 patients were implanted in immunodeficient mice. The expression was evaluated by immunohistochemistry. Patient and characteristics as well expressions compared using Chi-square test. independent prediction parameters identified logistic regression analyses.The rate HCC 39.47% (30/76). Tumors younger elevated preoperative alpha-fetoprotein level had higher rates. poor differentiation vascular invasion related to success. positive CK19, CD133, glypican-3 (GPC3), Ki67 Logistic analyses indicated that GPC3 two strongest predictors engraftment. GPC3/Ki67 phenotypes showed heterogeneous rates, 71.9% GPC3+/Ki67+ tumors, 30.8% GPC3-/Ki67+ 15.0% GPC3+/Ki67- 0 GPC3-/Ki67- tumors.Successful PDXs significantly features. phenotype most likely successfully establish PDXs.